Varsity students in Covid-19 diagnosis breakthrough
George Maponga –
Masvingo Bureau
In what is likely to be a major scientific breakthrough once formally certified, a former Great Zimbabwe University (GZU) student and a third-year student at the National University of Science and Technology (NUST) have designed computer software they say can distinguish ordinary pneumonia from the one caused by Covid-19.
The two pioneers of the system say the software will give impetus to the fight against Covid-19 as it will help in diagnosis and management of people affected by the virus, which has infected over 92 million people across the world in the past year.
Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy Platform
Diagnostic and Analytics Company Aims to Revolutionize Laboratory Testing and Analytics
News provided by
Share this article
SAN DIEGO, Jan. 11, 2021 /PRNewswire/
Genalyte, a leading diagnostics and analytics company, announced today the closure of $50 million in financing. Genalyte s Maverick™ Diagnostic System (MDS) uses silicon chip based photonic ring resonance technology to perform multiple, simultaneous, rapid tests on a small volume of whole blood or serum in twenty minutes. We are energized by the very enthusiastic response from Investors for this latest round of funding, said CEO Ashraf Hanna. Genalyte is uniquely positioned to improve the laboratory diagnostic and analytic space. We ve demonstrated the strength of our technology in our EUA authorized SARS-CoV-2 Multi-Antigen Serology Panel, which is able to measure 26 different antibodies from one dro
Font : A-A+
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. Myriads myChoice test is the only one of its kind to be approved for reimbursement in Japan, said Nicole Lambert, president of Myriad Genetic Laboratories. This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.
Posted January 8th, 2021 for Myriad SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.”